Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ken Masuo to Become Japan Representative for Oncology Business: AZ
May 25, 2015
- Blopress AG Share Tops 60% in Generic Market, Aims for Further Growth: ASKA President Yamaguchi
May 25, 2015
- 180 Billion Yen Sales in FY2017 Is “Quite Reachable”: Meiji Seika Pharma President
May 22, 2015
- Oncologics Retain Top Position in Therapeutic Category Sales Ranking in FY2014: IMS
May 22, 2015
- Japan Pharma Market Down by 0.6% to Under 10 Trillion Yen in FY2014: IMS
May 22, 2015
- Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
- “4-Company Oligopoly” on Seasonal Flu Vaccines Coming to an End, Era of Mega-Competition Coming to Japan: Dr Yamanishi of BIKEN
May 21, 2015
- Daiichi Sankyo, Takeda to Join in Distribution of Kaketsuken’s Seasonal Influenza Vaccine “to Bolster Stable Supplies”
May 21, 2015
- Otsuka to Launch Abilify Intramuscular Injectable on May 25
May 21, 2015
- Eisai Makes World’s 2nd Launch of Lenvima for Thyroid Cancer in Japan following US
May 21, 2015
- Gilead to Launch Sovaldi on May 25, with Proper Use Promotion by 150 Sales Reps
May 21, 2015
- Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
- R-Tech Ueno Ties Up with Hokkaido University to Develop VAP-1 Inhibitor
May 20, 2015
- Quintiles Acquires Clio Science to Enhance Oncology, CNS Expertise
May 20, 2015
- Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
- Japan’s Biosimilar Market to Rise to 31.4 Billion Yen in 2017: Fuji Keizai
May 19, 2015
- Sanofi Launches Menactra, Preventive Vaccine for Invasive Meningococcal Diseases
May 19, 2015
- Takeda Sees Lower Japan Sales for FY2015 on Generic Pressure
May 18, 2015
- Takeda Incurs Huge Red Ink on Actos Settlement, CEO Says Financial Uncertainty Lessened
May 18, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…